文献速递肾小球疾病急性肾损伤

血清胍基化YB-1提示活动性狼疮肾炎

Serum levels of guanidinylated YB-1 indicate active lupus nephritis.
PubMed 文献 · Nephrol Dial Transplant · 2026-08-26

该研究采用MALDI质谱在发现队列(n=50)及独立SLE队列(n=38)中定量血清YB-1-2G,发现其在疾病高活动度及活检证实的狼疮肾炎患者中显著更常见,尤其增殖型(III/IV型)和复发型;血清YB-1-2G诊断LN的敏感性85%、特异性70%、AUC=0.852。

要点

  • 血清YB-1-2G与SLE疾病高活动度及活检证实的活动性LN相关。
  • 血清YB-1-2G诊断LN敏感性85%、特异性70%、AUC=0.852。
  • 尿YB-1-2G及血清YB-1-3G的提示价值均不及血清YB-1-2G。

核心结论

  • 胍基化YB-1与SLE患者疾病复发及肾脏活动相关,YB-1-2G及其自身抗体具备生物标志物特征,值得在更大狼疮队列中进一步评估。

研究设计与样本

  • 采用MALDI质谱定量血清YB-1-2G,发现队列n=50,并在独立SLE队列n=38中验证,同时分析尿液样本及抗YB-1-2G自身抗体。

主要发现

  • 血清YB-1-2G在SLE高疾病活动度及活检证实的LN患者中显著更常见,尤其增殖型(III、IV型)和复发型LN。
  • 血清YB-1-2G诊断LN敏感性85%、特异性70%,AUC=0.852,对SLE肾脏受累有较强判别力。
  • 血清中检出YB-1-3G,LN患者尿中可检出YB-1-2G,但两者提示价值均不及血清YB-1-2G;复发时血清与尿YB-1-2G一致率更高。
  • 狼疮倾向小鼠及LN患者血清中检出抗YB-1-2G自身抗体,证实其免疫原性。

关键数值与推荐

  • 血清YB-1-2G诊断LN:敏感性85%,特异性70%,AUC=0.852。

临床怎么用

  • 血清YB-1-2G有望作为无创指标辅助识别SLE患者的活动性LN,尤其增殖型和复发型,但尚需更大队列验证后方可用于临床决策。

局限性

  • 发现队列与验证队列样本量较小(n=50、n=38),作者指出需在更大狼疮队列中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: Lupus nephritis (LN) is one of the most severe organ manifestations of systemic lupus erythematosus (SLE). Timely detection of LN is crucial to prompt early treatment and prevent kidney damage. Kidney biopsy remains the gold standard for LN diagnosis. Previous studies linked a guanidinylated form of cold-shock protein Y-box binding protein (YB)-1, denoted YB-1-2G, to SLE pathogenesis. We hypothesized that the presence of YB-1-2G associates with active LN and may serve as new biomarker candidate. METHODS: Using MALDI mass spectrometry (MS), we quantified serum YB-1-2G levels in our expanded discovery cohort (n=50) and, for the first time, associated YB-1-2G with clinical and serological markers of disease activity, as well as histological LN classes. These findings were corroborated in a second, independent SLE cohort (n=38). Furthermore, YB-1-2G was analyzed in urine samples, and a novel guanidinylated YB-1 variant with three modified lysine residues (YB-1-3G) was identified in serum. The presence of autoantibodies against YB-1-2G was assessed via peptide-based binding assays. RESULTS: Serum YB-1-2G was significantly more prevalent in SLE patients with high disease activity and biopsy-proven LN, particularly in proliferative (classes III and IV) and flaring LN forms. Serum YB-1-2G exhibited a sensitivity of 85% for the presence of LN, a specificity of 70%, with strong discriminatory power indicative for kidney involvement in SLE patients (AUC=0.852). YB-1-3G was found in serum and YB-1-2G was also detectable in urine samples from LN patients, yet both were less indicative than serum YB-1-2G. Concordance rates between serum and urinary YB-1-2G were higher during flares. YB-1-2G immunogenicity was confirmed by circulating anti-YB-1-2G autoantibodies in lupus-prone mice and in LN patient sera. CONCLUSIONS: We demonstrate that guanidinylated YB-1 is associated with disease flares and renal activity in SLE patients. Both, YB-1-2G and its autoantibodies exhibit key biomarker traits and warrant further evaluation in larger lupus cohorts.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Rauen T, Leitz A, Vogt K, et al. Serum levels of guanidinylated YB-1 indicate active lupus nephritis. Nephrol Dial Transplant. 2026. PMID: 42644661. doi:10.1093/ndt/gfag195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。